North America Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
In this region, North America Drug Delivery Market is projected to reach USD 823.55 billion by 2024 from USD 501.37 billion in 2016, at a CAGR of 6.4% in the forecast period 2017 to 2024.
Based on geography, the North America drug delivery market is segmented into 3 geographical regions, such as,
Johnson & Johnson Services, Inc., is going to dominate the North America drug delivery market followed by Novartis AG along with others such as
On the basis of route of administration the market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal.
Oral drug is further segmented based on form into solid drug, semi-solid drug and liquid drug. The solid drugs include and are categorized as tablets, capsules, powders and pills.
The semi-solid drugs are further segmented into gels, emulsions and elixirs. The liquid drugs are further classified into solutions and syrups. The Injectable drug delivery segment is further segmented into devices and formulations.
The devices segment is categorized as conventional injections, self-injectable devices, Needle free injectors, auto injectors, pen injectors, wearable injectors, other devices.
The convention injections sub-segment is further classified by material into glass and plastic injections, by usability disposable and reusable injections and, by type into fillable and pre-filled syringes.
The injectable drug delivery formulations are categorized as conventional drug delivery, novel drug delivery, long acting Injectable.
The pulmonary drug delivery segment is further classified into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers.
The nebulizers are further sub segmented into jet nebulizers, ultrasonic nebulizers and soft mist nebulizers.
Ocular drug delivery is segmented into liquid ocular drugs, semi solid ocular drugs and ocular devices. Liquid ocular drug delivery includes eye drops and liquid sprays.
Nasal drug delivery is segmented into nasal drops, powders, gels, and sprays. The topical drug delivery segment is segmented based on form into liquid, semi-solid, solid and transdermal.
The transdermal topical drug delivery includes transdermal patches and transdermal gels. The implantable drug delivery devices segment includes active and passive implantable drug delivery devices.
The transmucosal drug delivery segment is sub segmented into oral transmucosal and others.
The oral transmucosal segment includes products such as buccal and sublingual drug delivery devices, while the others segment includes rectal transmucosal drug delivery and vaginal transmucosal drug delivery.
On the basis of distribution channel the North America drug delivery market is segmented into hospital pharmacies, pharmacy stores, direct tenders and online pharmacy.
On the basis of end users the market is segmented into hospitals, over the counter, clinics, home healthcare, community healthcare, and others.
Based on geography, the North America drug delivery market is segmented into 3 geographical regions, such as,
- U.S.
- Mexico
- Canada
Johnson & Johnson Services, Inc., is going to dominate the North America drug delivery market followed by Novartis AG along with others such as
- F. Hoffmann-La Roche AG
- Pfizer, Inc.
- GlaxoSmithKline plc.
- Merck & Co., Sanofi
- Antares Pharma
- 3M
- Becton Dickinson and Company
- Nemera, Cima Labs, Inc.
- Dali Medical Devices
- Alkermes, Foamis
- Ypsomed
- Skyepharma AG
- Valeant Pharmaceuticals
- DSM Biomedical
- Catalent, Inc.
On the basis of route of administration the market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal.
Oral drug is further segmented based on form into solid drug, semi-solid drug and liquid drug. The solid drugs include and are categorized as tablets, capsules, powders and pills.
The semi-solid drugs are further segmented into gels, emulsions and elixirs. The liquid drugs are further classified into solutions and syrups. The Injectable drug delivery segment is further segmented into devices and formulations.
The devices segment is categorized as conventional injections, self-injectable devices, Needle free injectors, auto injectors, pen injectors, wearable injectors, other devices.
The convention injections sub-segment is further classified by material into glass and plastic injections, by usability disposable and reusable injections and, by type into fillable and pre-filled syringes.
The injectable drug delivery formulations are categorized as conventional drug delivery, novel drug delivery, long acting Injectable.
The pulmonary drug delivery segment is further classified into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers.
The nebulizers are further sub segmented into jet nebulizers, ultrasonic nebulizers and soft mist nebulizers.
Ocular drug delivery is segmented into liquid ocular drugs, semi solid ocular drugs and ocular devices. Liquid ocular drug delivery includes eye drops and liquid sprays.
Nasal drug delivery is segmented into nasal drops, powders, gels, and sprays. The topical drug delivery segment is segmented based on form into liquid, semi-solid, solid and transdermal.
The transdermal topical drug delivery includes transdermal patches and transdermal gels. The implantable drug delivery devices segment includes active and passive implantable drug delivery devices.
The transmucosal drug delivery segment is sub segmented into oral transmucosal and others.
The oral transmucosal segment includes products such as buccal and sublingual drug delivery devices, while the others segment includes rectal transmucosal drug delivery and vaginal transmucosal drug delivery.
On the basis of distribution channel the North America drug delivery market is segmented into hospital pharmacies, pharmacy stores, direct tenders and online pharmacy.
On the basis of end users the market is segmented into hospitals, over the counter, clinics, home healthcare, community healthcare, and others.
1. INTRODUCTION
1.1. OVERVIEW OF NORTH AMERICA DRUG DELIVERY DEVICES MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
3.1.2. GROWTH IN THE DEVELOPMENT OF BIOLOGICS
3.1.3. TECHNOLOGICAL DEVELOPMENT
3.2. RESTRAINTS
3.2.1. RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
3.3. OPPORTUNITIES
3.3.1. RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
3.3.2. RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
3.3.3. TREND OF MERGER AND ACQUISITIONS, AND COLLABORATIONS
3.3.4. FOCUS ON PATIENT NEEDS
3.3.5. DEVELOPING AND NEW EMERGING REVENUE POCKETS
3.4. THREATS
3.4.1. PRODUCT RECALLS
3.4.2. STRINGENT REGULATORY AND HIGH PRICING
3.4.3. PATENT EXPIRY AND PATENT CLIFF
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. NORTH AMERICA ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.3. NORTH AMERICA SOLID ORAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.4. NORTH AMERICA LIQUID ORAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.5. NORTH AMERICA SEMI-SOLID ORAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.6. NORTH AMERICA PULMONARY DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.7. NORTH AMERICA NEBULIZERS MARKET, BY PRODUCT TYPE
6.8. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.9. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES,
BY PRODUCT TYPE
6.9.1. NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET
6.9.2. NORTH AMERICA SELF-INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.10. NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
6.11. NORTH AMERICA OPHTHALMIC DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.12. NORTH AMERICA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET,BY FORM
6.13. OPHTHALMIC DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.14. NORTH AMERICA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.15. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.16. NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.17. NORTH AMERICA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
6.17.1. NORTH AMERICA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE
6.17.2. NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE
6.17.3. NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE
6.18. NORTH AMERICA IMPLANTABLE DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.19. NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.20. NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.21. NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
7. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER
7.1. OVERVIEW
8. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
9. DRUG DELIVERY MARKET, BY GEOGRAPHY
9.1. NORTH AMERICA DRUG DELIVERY DEVICES MARKET
9.2. U.S. DRUG DELIVERY DEVICES MARKET
9.3. CANADA DRUG DELIVERY DEVICES MARKET
9.4. MEXICO DRUG DELIVERY DEVICES MARKET
10. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, COMPANY SHARE
10.1. COMPANY SHARE ANALYSIS: NORTH AMERICA
11. COMPANY PROFILES
11.1. BAYER AG
11.1.1. COMPANY OVERVIEW
11.1.2. REVENUE ANALYSIS
11.1.3. PRODUCT PORTFOLIO
11.1.4. RECENT DEVELOPMENTS
11.2. F. HOFFMANN-LA ROCHE LTD
11.2.1. COMPANY OVERVIEW
11.2.2. REVENUE ANALYSIS
11.2.3. PRODUCT PORTFOLIO
11.2.4. RECENT DEVELOPMENTS
11.3. GLAXOSMITHKLINE PLC
11.3.1. COMPANY OVERVIEW
11.3.2. REVENUE ANALYSIS
11.3.3. PRODUCT PORTFOLIO
11.3.4. RECENT DEVELOPMENTS
11.4. JOHNSON & JOHNSON SERVICES, INC.
11.4.1. COMPANY OVERVIEW
11.4.2. REVENUE ANALYSIS
11.4.3. PRODUCT PORTFOLIO
11.4.4. RECENT DEVELOPMENTS
11.5. NOVARTIS
11.5.1. COMPANY OVERVIEW
11.5.2. REVENUE ANALYSIS
11.5.3. PRODUCT PORTOFOLIO
11.5.4. RECENT DEVELOPMENTS
11.6. PFIZER, INC.
11.6.1. COMPANY OVERVIEW
11.6.2. REVENUE ANALYSIS
11.6.3. PRODUCT PORTFOLIO
11.6.4. RECENT DEVELOPMENTS
11.7. 3M
11.7.1. COMPANY OVERVIEW
11.7.2. REVENUE ANALYSIS
11.7.3. PRODUCT PORTFOLIO
11.7.4. RECENT DEVELOPMENTS
11.8. ANTARES PHARMA, INC.
11.8.1. COMPANY OVERVIEW
11.8.2. REVENUE ANALYSIS
11.8.3. PRODUCT PORTFOLIO
11.8.4. RECENT DEVELOPMENTS
11.9. MERCK & CO.
11.9.1. COMPANY OVERVIEW
11.9.2. REVENUE ANALYSIS
11.9.3. PRODUCT PORTFOLIO
11.9.4. RECENT DEVELOPMENTS
11.10. SANOFI
11.10.1. COMPANY OVERVIEW
11.10.2. REVENUE ANALYSIS
11.10.3. PRODUCT PORTOFOLIO
11.10.4. RECENT DEVELOPMENTS
12. RELATED REPORTS
1.1. OVERVIEW OF NORTH AMERICA DRUG DELIVERY DEVICES MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
3.1.2. GROWTH IN THE DEVELOPMENT OF BIOLOGICS
3.1.3. TECHNOLOGICAL DEVELOPMENT
3.2. RESTRAINTS
3.2.1. RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
3.3. OPPORTUNITIES
3.3.1. RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
3.3.2. RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
3.3.3. TREND OF MERGER AND ACQUISITIONS, AND COLLABORATIONS
3.3.4. FOCUS ON PATIENT NEEDS
3.3.5. DEVELOPING AND NEW EMERGING REVENUE POCKETS
3.4. THREATS
3.4.1. PRODUCT RECALLS
3.4.2. STRINGENT REGULATORY AND HIGH PRICING
3.4.3. PATENT EXPIRY AND PATENT CLIFF
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. NORTH AMERICA ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.3. NORTH AMERICA SOLID ORAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.4. NORTH AMERICA LIQUID ORAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.5. NORTH AMERICA SEMI-SOLID ORAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.6. NORTH AMERICA PULMONARY DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.7. NORTH AMERICA NEBULIZERS MARKET, BY PRODUCT TYPE
6.8. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.9. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES,
BY PRODUCT TYPE
6.9.1. NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET
6.9.2. NORTH AMERICA SELF-INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.10. NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
6.11. NORTH AMERICA OPHTHALMIC DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.12. NORTH AMERICA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET,BY FORM
6.13. OPHTHALMIC DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.14. NORTH AMERICA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.15. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.16. NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.17. NORTH AMERICA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
6.17.1. NORTH AMERICA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE
6.17.2. NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE
6.17.3. NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE
6.18. NORTH AMERICA IMPLANTABLE DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.19. NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE
6.20. NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.21. NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
7. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER
7.1. OVERVIEW
8. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
9. DRUG DELIVERY MARKET, BY GEOGRAPHY
9.1. NORTH AMERICA DRUG DELIVERY DEVICES MARKET
9.2. U.S. DRUG DELIVERY DEVICES MARKET
9.3. CANADA DRUG DELIVERY DEVICES MARKET
9.4. MEXICO DRUG DELIVERY DEVICES MARKET
10. NORTH AMERICA DRUG DELIVERY DEVICES MARKET, COMPANY SHARE
10.1. COMPANY SHARE ANALYSIS: NORTH AMERICA
11. COMPANY PROFILES
11.1. BAYER AG
11.1.1. COMPANY OVERVIEW
11.1.2. REVENUE ANALYSIS
11.1.3. PRODUCT PORTFOLIO
11.1.4. RECENT DEVELOPMENTS
11.2. F. HOFFMANN-LA ROCHE LTD
11.2.1. COMPANY OVERVIEW
11.2.2. REVENUE ANALYSIS
11.2.3. PRODUCT PORTFOLIO
11.2.4. RECENT DEVELOPMENTS
11.3. GLAXOSMITHKLINE PLC
11.3.1. COMPANY OVERVIEW
11.3.2. REVENUE ANALYSIS
11.3.3. PRODUCT PORTFOLIO
11.3.4. RECENT DEVELOPMENTS
11.4. JOHNSON & JOHNSON SERVICES, INC.
11.4.1. COMPANY OVERVIEW
11.4.2. REVENUE ANALYSIS
11.4.3. PRODUCT PORTFOLIO
11.4.4. RECENT DEVELOPMENTS
11.5. NOVARTIS
11.5.1. COMPANY OVERVIEW
11.5.2. REVENUE ANALYSIS
11.5.3. PRODUCT PORTOFOLIO
11.5.4. RECENT DEVELOPMENTS
11.6. PFIZER, INC.
11.6.1. COMPANY OVERVIEW
11.6.2. REVENUE ANALYSIS
11.6.3. PRODUCT PORTFOLIO
11.6.4. RECENT DEVELOPMENTS
11.7. 3M
11.7.1. COMPANY OVERVIEW
11.7.2. REVENUE ANALYSIS
11.7.3. PRODUCT PORTFOLIO
11.7.4. RECENT DEVELOPMENTS
11.8. ANTARES PHARMA, INC.
11.8.1. COMPANY OVERVIEW
11.8.2. REVENUE ANALYSIS
11.8.3. PRODUCT PORTFOLIO
11.8.4. RECENT DEVELOPMENTS
11.9. MERCK & CO.
11.9.1. COMPANY OVERVIEW
11.9.2. REVENUE ANALYSIS
11.9.3. PRODUCT PORTFOLIO
11.9.4. RECENT DEVELOPMENTS
11.10. SANOFI
11.10.1. COMPANY OVERVIEW
11.10.2. REVENUE ANALYSIS
11.10.3. PRODUCT PORTOFOLIO
11.10.4. RECENT DEVELOPMENTS
12. RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2016 35
TABLE 2 LIST OF FDA APPROVED GENERICS, IN 2016 40
TABLE 3 MAJOR PRODUCT RECALLS IN THE DRUG DELIVERY MARKET, 2016 43
TABLE 4 PATENT EXPIRY OF DRUGS, 2015-2017 45
TABLE 5 NORTH AMERICA DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 56
TABLE 6 NORTH AMERICA ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 57
TABLE 7 NORTH AMERICA SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 59
TABLE 8 NORTH AMERICA LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 61
TABLE 9 NORTH AMERICA SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 63
TABLE 10 NORTH AMERICA PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 66
TABLE 11 NORTH AMERICA NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 68
TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 70
TABLE 13 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 71
TABLE 14 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 74
TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 75
TABLE 16 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 76
TABLE 17 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 79
TABLE 18 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 82
TABLE 19 NORTH AMERICA OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 83
TABLE 20 NORTH AMERICA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 86
TABLE 21 NORTH AMERICA LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 87
TABLE 22 NORTH AMERICA SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 87
TABLE 23 NORTH AMERICA OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 89
TABLE 24 NORTH AMERICA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 91
TABLE 25 NORTH AMERICA TOPICAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 93
TABLE 26 NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 95
TABLE 27 NORTH AMERICA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 96
TABLE 28 NORTH AMERICA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 98
TABLE 29 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 100
TABLE 30 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 101
TABLE 31 NORTH AMERICA IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 103
TABLE 32 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 105
TABLE 33 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 107
TABLE 34 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 109
TABLE 35 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2015 – 2024 (USD BILLION) 112
TABLE 36 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION) 116
TABLE 37 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2015 – 2024 (USD BILLION) 120
TABLE 38 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 122
TABLE 39 NORTH AMERICA ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 123
TABLE 40 NORTH AMERICA SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 123
TABLE 41 NORTH AMERICA LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 124
TABLE 42 NORTH AMERICA SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 124
TABLE 43 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 125
TABLE 44 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 125
TABLE 45 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 126
TABLE 46 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 126
TABLE 47 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 127
TABLE 48 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 127
TABLE 49 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 128
TABLE 50 NORTH AMERICA OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 128
TABLE 51 NORTH AMERICA OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 129
TABLE 52 NORTH AMERICA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 129
TABLE 53 NORTH AMERICA LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 130
TABLE 54 NORTH AMERICA SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 130
TABLE 55 NORTH AMERICA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 131
TABLE 56 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 131
TABLE 57 NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 132
TABLE 58 NORTH AMERICA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 132
TABLE 59 NORTH AMERICA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 133
TABLE 60 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 133
TABLE 61 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 134
TABLE 62 NORTH AMERICA IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 134
TABLE 63 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 135
TABLE 64 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 136
TABLE 65 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 136
TABLE 66 NORTH AMERICA PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 137
TABLE 67 NORTH AMERICA NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 137
TABLE 68 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 138
TABLE 69 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 139
TABLE 70 U.S. DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 142
TABLE 71 U.S. ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 143
TABLE 72 U.S. SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 143
TABLE 73 U.S. LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 144
TABLE 74 U.S. SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 144
TABLE 75 U.S. INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 145
TABLE 76 U.S. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 145
TABLE 77 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 146
TABLE 78 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2017 – 2024 (USD BILLION) 146
TABLE 79 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 147
TABLE 80 U.S. SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 147
TABLE 81 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 148
TABLE 82 U.S. OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017 – 2024 (USD BILLION) 148
TABLE 83 U.S. OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 149
TABLE 84 U.S. OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 149
TABLE 85 U.S. LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 150
TABLE 86 U.S. SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 150
TABLE 87 U.S. NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 151
TABLE 88 U.S. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 151
TABLE 89 U.S. TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 152
TABLE 90 U.S. TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 152
TABLE 91 U.S. SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 153
TABLE 92 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 153
TABLE 93 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 154
TABLE 94 U.S. IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 154
TABLE 95 U.S. TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 155
TABLE 96 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 155
TABLE 97 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 156
TABLE 98 U.S. PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 156
TABLE 99 U.S. NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 157
TABLE 100 U.S. DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 157
TABLE 101 U.S. DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 158
TABLE 102 CANADA DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 161
TABLE 103 CANADA ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 162
TABLE 104 CANADA SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 162
TABLE 105 CANADA LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 163
TABLE 106 CANADA SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 163
TABLE 107 CANADA INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 164
TABLE 108 CANADA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 164
TABLE 109 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 165
TABLE 110 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 165
TABLE 111 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 166
TABLE 112 CANADA SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 166
TABLE 113 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 167
TABLE 114 CANADA OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 167
TABLE 115 CANADA OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 168
TABLE 116 CANADA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 168
TABLE 117 CANADA LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 169
TABLE 118 CANADA SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 169
TABLE 119 CANADA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 170
TABLE 120 CANADA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 170
TABLE 121 CANADA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 171
TABLE 122 CANADA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 171
TABLE 123 CANADA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 172
TABLE 124 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 172
TABLE 125 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 173
TABLE 126 CANADA IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 173
TABLE 127 U.S. TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 174
TABLE 128 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 174
TABLE 129 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 175
TABLE 130 CANADA PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 175
TABLE 131 CANADA NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 176
TABLE 132 CANADA DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 176
TABLE 133 CANADA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 177
TABLE 134 MEXICO DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 179
TABLE 135 MEXICO ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 180
TABLE 136 MEXICO SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 180
TABLE 137 MEXICO LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 181
TABLE 138 MEXICO SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 181
TABLE 139 MEXICO INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 182
TABLE 140 MEXICO INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 182
TABLE 141 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 183
TABLE 142 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 183
TABLE 143 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 184
TABLE 144 MEXICO SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 184
TABLE 145 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 185
TABLE 146 MEXICO OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 185
TABLE 147 MEXICO OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 186
TABLE 148 MEXICO OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 186
TABLE 149 MEXICO LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 187
TABLE 150 MEXICO SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 187
TABLE 151 MEXICO NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 188
TABLE 152 MEXICO TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 188
TABLE 153 MEXICO TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 189
TABLE 154 MEXICO TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 189
TABLE 155 MEXICO SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 190
TABLE 156 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 190
TABLE 157 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 191
TABLE 158 MEXICO IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 191
TABLE 159 MEXICO TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 192
TABLE 160 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 192
TABLE 161 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 193
TABLE 162 MEXICO PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 193
TABLE 163 MEXICO NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 194
TABLE 164 CANADA DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 195
TABLE 165 MEXICO DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 195
TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2016 35
TABLE 2 LIST OF FDA APPROVED GENERICS, IN 2016 40
TABLE 3 MAJOR PRODUCT RECALLS IN THE DRUG DELIVERY MARKET, 2016 43
TABLE 4 PATENT EXPIRY OF DRUGS, 2015-2017 45
TABLE 5 NORTH AMERICA DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 56
TABLE 6 NORTH AMERICA ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 57
TABLE 7 NORTH AMERICA SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 59
TABLE 8 NORTH AMERICA LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 61
TABLE 9 NORTH AMERICA SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 63
TABLE 10 NORTH AMERICA PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 66
TABLE 11 NORTH AMERICA NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 68
TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 70
TABLE 13 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 71
TABLE 14 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 74
TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 75
TABLE 16 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 76
TABLE 17 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 79
TABLE 18 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 82
TABLE 19 NORTH AMERICA OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 83
TABLE 20 NORTH AMERICA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 86
TABLE 21 NORTH AMERICA LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 87
TABLE 22 NORTH AMERICA SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 87
TABLE 23 NORTH AMERICA OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 89
TABLE 24 NORTH AMERICA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 91
TABLE 25 NORTH AMERICA TOPICAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 93
TABLE 26 NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 95
TABLE 27 NORTH AMERICA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 96
TABLE 28 NORTH AMERICA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 98
TABLE 29 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 100
TABLE 30 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 101
TABLE 31 NORTH AMERICA IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 103
TABLE 32 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 105
TABLE 33 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 107
TABLE 34 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 109
TABLE 35 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2015 – 2024 (USD BILLION) 112
TABLE 36 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION) 116
TABLE 37 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2015 – 2024 (USD BILLION) 120
TABLE 38 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 122
TABLE 39 NORTH AMERICA ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 123
TABLE 40 NORTH AMERICA SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 123
TABLE 41 NORTH AMERICA LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 124
TABLE 42 NORTH AMERICA SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 124
TABLE 43 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 125
TABLE 44 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 125
TABLE 45 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 126
TABLE 46 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 126
TABLE 47 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 127
TABLE 48 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 127
TABLE 49 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 128
TABLE 50 NORTH AMERICA OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 128
TABLE 51 NORTH AMERICA OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 129
TABLE 52 NORTH AMERICA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 129
TABLE 53 NORTH AMERICA LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 130
TABLE 54 NORTH AMERICA SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 130
TABLE 55 NORTH AMERICA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 131
TABLE 56 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 131
TABLE 57 NORTH AMERICA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 132
TABLE 58 NORTH AMERICA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 132
TABLE 59 NORTH AMERICA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 133
TABLE 60 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 133
TABLE 61 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 134
TABLE 62 NORTH AMERICA IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 134
TABLE 63 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 135
TABLE 64 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 136
TABLE 65 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 136
TABLE 66 NORTH AMERICA PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 137
TABLE 67 NORTH AMERICA NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 137
TABLE 68 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 138
TABLE 69 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 139
TABLE 70 U.S. DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 142
TABLE 71 U.S. ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 143
TABLE 72 U.S. SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 143
TABLE 73 U.S. LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 144
TABLE 74 U.S. SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 144
TABLE 75 U.S. INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 145
TABLE 76 U.S. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 145
TABLE 77 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 146
TABLE 78 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2017 – 2024 (USD BILLION) 146
TABLE 79 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 147
TABLE 80 U.S. SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 147
TABLE 81 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 148
TABLE 82 U.S. OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017 – 2024 (USD BILLION) 148
TABLE 83 U.S. OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 149
TABLE 84 U.S. OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 149
TABLE 85 U.S. LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 150
TABLE 86 U.S. SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 150
TABLE 87 U.S. NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 151
TABLE 88 U.S. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 151
TABLE 89 U.S. TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 152
TABLE 90 U.S. TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 152
TABLE 91 U.S. SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 153
TABLE 92 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 153
TABLE 93 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 154
TABLE 94 U.S. IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 154
TABLE 95 U.S. TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 155
TABLE 96 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 155
TABLE 97 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 156
TABLE 98 U.S. PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 156
TABLE 99 U.S. NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 157
TABLE 100 U.S. DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 157
TABLE 101 U.S. DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 158
TABLE 102 CANADA DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 161
TABLE 103 CANADA ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 162
TABLE 104 CANADA SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 162
TABLE 105 CANADA LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 163
TABLE 106 CANADA SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 163
TABLE 107 CANADA INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 164
TABLE 108 CANADA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 164
TABLE 109 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 165
TABLE 110 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 165
TABLE 111 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 166
TABLE 112 CANADA SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 166
TABLE 113 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 167
TABLE 114 CANADA OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 167
TABLE 115 CANADA OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 168
TABLE 116 CANADA OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 168
TABLE 117 CANADA LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 169
TABLE 118 CANADA SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 169
TABLE 119 CANADA NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 170
TABLE 120 CANADA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 170
TABLE 121 CANADA TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 171
TABLE 122 CANADA TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 171
TABLE 123 CANADA SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 172
TABLE 124 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 172
TABLE 125 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 173
TABLE 126 CANADA IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 173
TABLE 127 U.S. TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 174
TABLE 128 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 174
TABLE 129 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 175
TABLE 130 CANADA PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 175
TABLE 131 CANADA NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 176
TABLE 132 CANADA DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 176
TABLE 133 CANADA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 177
TABLE 134 MEXICO DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2015 – 2024 (USD BILLION) 179
TABLE 135 MEXICO ORAL DRUG DELIVERY MARKET, BY FORM, 2015 – 2024 (USD BILLION) 180
TABLE 136 MEXICO SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 180
TABLE 137 MEXICO LIQUID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 181
TABLE 138 MEXICO SEMI-SOLID ORAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 181
TABLE 139 MEXICO INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 182
TABLE 140 MEXICO INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 182
TABLE 141 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2015 – 2024 (USD BILLION) 183
TABLE 142 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 183
TABLE 143 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2015 – 2024 (USD BILLION) 184
TABLE 144 MEXICO SELF INJECTION DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 184
TABLE 145 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 185
TABLE 146 MEXICO OPHTHALMIC DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 185
TABLE 147 MEXICO OPHTHALMIC DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 186
TABLE 148 MEXICO OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 186
TABLE 149 MEXICO LIQUID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 187
TABLE 150 MEXICO SEMI SOLID OPHTHALMIC DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 187
TABLE 151 MEXICO NASAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 188
TABLE 152 MEXICO TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 188
TABLE 153 MEXICO TRANSDERMAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 189
TABLE 154 MEXICO TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY FORM, 2015 – 2024 (USD BILLION) 189
TABLE 155 MEXICO SEMI SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 190
TABLE 156 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 190
TABLE 157 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2015 – 2024 (USD BILLION) 191
TABLE 158 MEXICO IMPLANTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 191
TABLE 159 MEXICO TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 192
TABLE 160 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 192
TABLE 161 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 193
TABLE 162 MEXICO PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 193
TABLE 163 MEXICO NEBULIZERS PULMONARY DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD BILLION) 194
TABLE 164 CANADA DRUG DELIVERY DEVICES MARKET, BY END USERS, 2015 – 2024 (USD BILLION) 195
TABLE 165 MEXICO DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD BILLION) 195
LIST OF FIGURES
FIGURE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION 24
FIGURE 2 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: GEOGRAHIC SCOPE 25
FIGURE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION 27
FIGURE 4 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: RESEARCH SNAPSHOT 28
FIGURE 5 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BOTTOM UP APPROACH 30
FIGURE 6 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: TOP DOWN APPROACH 30
FIGURE 7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: INTERVIEWS BY COUNTRY AND DESIGNATION 31
FIGURE 8 NORTH AMERICA DOMINATES THE MARKET FOR DRUG DELIVERY DEVICES IN 2016 AND IS EXPECTED TO CONTINUE THIS TREND IN THE FORECAST PERIOD TO 2024 48
FIGURE 9 TECHNOLOGICAL DEVELOPMENT IN SELF ADMINISTERED AND NON-INVASIVE DRUG DELIVERY TECHNOLOGIES IS EXPECTED TO DRIVE THE MARKET FOR NORTH AMERICA DRUG DELIVERY DEVICES IN THE FORECAST PERIOD 2017 TO 2024 49
FIGURE 10 ORAL DRUG DELIVERY MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET IN 2024 50
FIGURE 11 UNITED STATES IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR NORTH AMERICA DRUG DELIVERY DEVICES MANUFACTURERS IN THE FORECAST PERIOD 2017 TO 2024 51
FIGURE 12 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, SNAPSHOT 2024 54
FIGURE 13 NORTH AMERICA DRUG DELIVERY MARKET: BY END-USER, SNAPSHOT 2016 111
FIGURE 14 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, SNAPSHOT 2016 115
FIGURE 15 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY COUNTRY, SNAPSHOT 2017& 2024 119
FIGURE 16 INJECTABLE DRUG DELIVERY IS EXPECTED TO BE GROWING AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN NORTH AMERICA DRUG DELIVERY DEVICES MARKET 121
FIGURE 17 INJECTABLE DRUG DELIVERY IS EXPECTED TO BE GROWING AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN U.S. DRUG DELIVERY DEVICES MARKET 141
FIGURE 18 INJECTABLE DRUG DELIVERY IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN CANADA DRUG DELIVERY DEVICES MARKET 160
FIGURE 19 INJECTABLE DRUG DELIVERY IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN MEXICO DRUG DELIVERY DEVICES MARKET 178
FIGURE 20 NORTH AMERICA DRUG DELIVERY MARKET: COMPANY SHARE 2016 (%) 197
FIGURE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION 24
FIGURE 2 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: GEOGRAHIC SCOPE 25
FIGURE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION 27
FIGURE 4 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: RESEARCH SNAPSHOT 28
FIGURE 5 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BOTTOM UP APPROACH 30
FIGURE 6 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: TOP DOWN APPROACH 30
FIGURE 7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: INTERVIEWS BY COUNTRY AND DESIGNATION 31
FIGURE 8 NORTH AMERICA DOMINATES THE MARKET FOR DRUG DELIVERY DEVICES IN 2016 AND IS EXPECTED TO CONTINUE THIS TREND IN THE FORECAST PERIOD TO 2024 48
FIGURE 9 TECHNOLOGICAL DEVELOPMENT IN SELF ADMINISTERED AND NON-INVASIVE DRUG DELIVERY TECHNOLOGIES IS EXPECTED TO DRIVE THE MARKET FOR NORTH AMERICA DRUG DELIVERY DEVICES IN THE FORECAST PERIOD 2017 TO 2024 49
FIGURE 10 ORAL DRUG DELIVERY MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET IN 2024 50
FIGURE 11 UNITED STATES IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR NORTH AMERICA DRUG DELIVERY DEVICES MANUFACTURERS IN THE FORECAST PERIOD 2017 TO 2024 51
FIGURE 12 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE, SNAPSHOT 2024 54
FIGURE 13 NORTH AMERICA DRUG DELIVERY MARKET: BY END-USER, SNAPSHOT 2016 111
FIGURE 14 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, SNAPSHOT 2016 115
FIGURE 15 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY COUNTRY, SNAPSHOT 2017& 2024 119
FIGURE 16 INJECTABLE DRUG DELIVERY IS EXPECTED TO BE GROWING AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN NORTH AMERICA DRUG DELIVERY DEVICES MARKET 121
FIGURE 17 INJECTABLE DRUG DELIVERY IS EXPECTED TO BE GROWING AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN U.S. DRUG DELIVERY DEVICES MARKET 141
FIGURE 18 INJECTABLE DRUG DELIVERY IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN CANADA DRUG DELIVERY DEVICES MARKET 160
FIGURE 19 INJECTABLE DRUG DELIVERY IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD IN MEXICO DRUG DELIVERY DEVICES MARKET 178
FIGURE 20 NORTH AMERICA DRUG DELIVERY MARKET: COMPANY SHARE 2016 (%) 197
